메뉴 건너뛰기




Volumn 21, Issue 8, 2015, Pages 914-921

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(35)  Rapoport, Aaron P a   Stadtmauer, Edward A b   Binder Scholl, Gwendolyn K c   Goloubeva, Olga a   Vogl, Dan T d   Lacey, Simon F e   Badros, Ashraf Z f   Garfall, Alfred e   Weiss, Brendan d   Finklestein, Jeffrey a   Kulikovskaya, Irina a   Sinha, Sanjoy K b   Kronsberg, Shari c   Gupta, Minnal a   Bond, Sarah d   Melchiori, Luca a   Brewer, Joanna E a   Bennett, Alan D a   Gerry, Andrew B a   Pumphrey, Nicholas J b   more..


Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; LAGE 1 ANTIGEN; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CTAG1B PROTEIN, HUMAN; CTAG2 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; SDC1 PROTEIN, HUMAN; SYNDECAN 1;

EID: 84938963928     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3910     Document Type: Article
Times cited : (711)

References (63)
  • 1
    • 0030043438 scopus 로고    scopus 로고
    • Graft-versus-myeloma effect: Proof of principle
    • Tricot, G. et al. Graft-versus-myeloma effect: proof of principle. Blood 87, 1196-1198 (1996).
    • (1996) Blood , vol.87 , pp. 1196-1198
    • Tricot, G.1
  • 2
    • 0035883066 scopus 로고    scopus 로고
    • T cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect
    • Alyea, E. et al. T cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 98, 934-939 (2001).
    • (2001) Blood , vol.98 , pp. 934-939
    • Alyea, E.1
  • 3
    • 2542448169 scopus 로고    scopus 로고
    • The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
    • Lokhorst, H.M. et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103, 4362-4364 (2004).
    • (2004) Blood , vol.103 , pp. 4362-4364
    • Lokhorst, H.M.1
  • 4
    • 0031001279 scopus 로고    scopus 로고
    • Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
    • Barlogie, B. et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89, 789-793 (1997).
    • (1997) Blood , vol.89 , pp. 789-793
    • Barlogie, B.1
  • 5
    • 8944220233 scopus 로고    scopus 로고
    • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
    • Attal, M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335, 91-97 (1996).
    • (1996) N. Engl. J. Med , vol.335 , pp. 91-97
    • Attal, M.1
  • 6
    • 0037739753 scopus 로고    scopus 로고
    • High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
    • Child, J.A. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348, 1875-1883 (2003).
    • (2003) N. Engl. J. Med , vol.348 , pp. 1875-1883
    • Child, J.A.1
  • 7
    • 0035437134 scopus 로고    scopus 로고
    • Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma
    • Porrata, L.F. et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98, 579-585 (2001).
    • (2001) Blood , vol.98 , pp. 579-585
    • Porrata, L.F.1
  • 8
    • 8644291446 scopus 로고    scopus 로고
    • Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation
    • Porrata, L.F. &Markovic, S.N. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin. Exp. Med. 4, 78-85 (2004).
    • (2004) Clin. Exp. Med , vol.4 , pp. 78-85
    • Porrata, L.F.1    Markovic, S.N.2
  • 9
    • 0036789934 scopus 로고    scopus 로고
    • T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells
    • Dhodapkar, M.V., Krasovsky, J. &Olson, K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc. Natl. Acad. Sci. USA 99, 13009-13013 (2002).
    • (2002) Proc. Natl. Acad. Sci. USA , vol.99 , pp. 13009-13013
    • Dhodapkar, M.V.1    Krasovsky, J.2    Olson, K.3
  • 10
    • 20144389307 scopus 로고    scopus 로고
    • Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors
    • Noonan, K. et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 65, 2026-2034 (2005).
    • (2005) Cancer Res , vol.65 , pp. 2026-2034
    • Noonan, K.1
  • 11
    • 30744454570 scopus 로고    scopus 로고
    • Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
    • Rapoport, A.P. et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11, 1230-1237 (2005).
    • (2005) Nat. Med , vol.11 , pp. 1230-1237
    • Rapoport, A.P.1
  • 12
    • 78751699860 scopus 로고    scopus 로고
    • Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma
    • Rapoport, A.P. et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117, 788-797 (2011).
    • (2011) Blood , vol.117 , pp. 788-797
    • Rapoport, A.P.1
  • 13
    • 84895813363 scopus 로고    scopus 로고
    • Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells
    • Rapoport, A.P. et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin. Cancer Res. 20, 1355-1365 (2014).
    • (2014) Clin. Cancer Res , vol.20 , pp. 1355-1365
    • Rapoport, A.P.1
  • 14
    • 67650360757 scopus 로고    scopus 로고
    • Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells
    • Rapoport, A.P. et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin. Cancer Res. 15, 4499-4507 (2009).
    • (2009) Clin. Cancer Res , vol.15 , pp. 4499-4507
    • Rapoport, A.P.1
  • 15
    • 78650969510 scopus 로고    scopus 로고
    • Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: Results of a randomized clinical trial
    • Stadtmauer, E.A. et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood 117, 63-71 (2011).
    • (2011) Blood , vol.117 , pp. 63-71
    • Stadtmauer, E.A.1
  • 16
    • 84879863520 scopus 로고    scopus 로고
    • Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients
    • Rosenblatt, J. et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin. Cancer Res. 19, 3640-3648 (2013).
    • (2013) Clin. Cancer Res , vol.19 , pp. 3640-3648
    • Rosenblatt, J.1
  • 17
    • 4644324025 scopus 로고    scopus 로고
    • Cancer immunotherapy: Moving beyond current vaccines
    • Rosenberg, S.A., Yang, J.C. &Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
    • (2004) Nat. Med , vol.10 , pp. 909-915
    • Rosenberg, S.A.1    Yang, J.C.2    Restifo, N.P.3
  • 18
    • 84871338258 scopus 로고    scopus 로고
    • Different affinity windows for virus and cancer-specific T-cell receptors: Implications for therapeutic strategies
    • Aleksic, M. et al. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol. 42, 3174-3179 (2012).
    • (2012) Eur. J. Immunol , vol.42 , pp. 3174-3179
    • Aleksic, M.1
  • 19
    • 33744938168 scopus 로고    scopus 로고
    • Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors
    • Purbhoo, M.A. et al. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J. Immunol. 176, 7308-7316 (2006).
    • (2006) J. Immunol , vol.176 , pp. 7308-7316
    • Purbhoo, M.A.1
  • 20
    • 84894107349 scopus 로고    scopus 로고
    • New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape
    • Mittal, D., Gubin, M.M., Schreiber, R.D. &Smyth, M.J. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 27, 16-25 (2014).
    • (2014) Curr. Opin. Immunol , vol.27 , pp. 16-25
    • Mittal, D.1    Gubin, M.M.2    Schreiber, R.D.3    Smyth, M.J.4
  • 21
    • 84908073316 scopus 로고    scopus 로고
    • Chimeric antigen receptor T cells for sustained remissions in leukemia
    • Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
    • (2014) N. Engl. J. Med , vol.371 , pp. 1507-1517
    • Maude, S.L.1
  • 22
    • 84899656300 scopus 로고    scopus 로고
    • Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
    • Davila, M.L. et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int. J. Hematol. 99, 361-371 (2014).
    • (2014) Int. J. Hematol , vol.99 , pp. 361-371
    • Davila, M.L.1
  • 23
    • 84923019006 scopus 로고    scopus 로고
    • T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial
    • Lee, D.W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, p517-p528 (2014).
    • (2014) Lancet , vol.385 , pp. p517-p528
    • Lee, D.W.1
  • 24
    • 33749624177 scopus 로고    scopus 로고
    • Cancer regression in patients after transfer of genetically engineered lymphocytes
    • Morgan, R.A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
    • (2006) Science , vol.314 , pp. 126-129
    • Morgan, R.A.1
  • 25
    • 70149114880 scopus 로고    scopus 로고
    • Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    • Johnson, L.A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 (2009).
    • (2009) Blood , vol.114 , pp. 535-546
    • Johnson, L.A.1
  • 26
    • 70449486486 scopus 로고    scopus 로고
    • Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation
    • Burns, W.R., Zheng, Z., Rosenberg, S.A. &Morgan, R.A. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114, 2888-2899 (2009).
    • (2009) Blood , vol.114 , pp. 2888-2899
    • Burns, W.R.1    Zheng, Z.2    Rosenberg, S.A.3    Morgan, R.A.4
  • 27
    • 21444445173 scopus 로고    scopus 로고
    • Directed evolution of human T-cell receptors with picomolar affinities by phage display
    • Li, Y. et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23, 349-354 (2005).
    • (2005) Nat. Biotechnol , vol.23 , pp. 349-354
    • Li, Y.1
  • 28
    • 44449128698 scopus 로고    scopus 로고
    • Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions
    • Robbins, P.F. et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180, 6116-6131 (2008).
    • (2008) J. Immunol , vol.180 , pp. 6116-6131
    • Robbins, P.F.1
  • 29
    • 79952304769 scopus 로고    scopus 로고
    • Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    • Robbins, P.F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924 (2011).
    • (2011) J. Clin. Oncol , vol.29 , pp. 917-924
    • Robbins, P.F.1
  • 30
    • 84961899942 scopus 로고    scopus 로고
    • A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response
    • Robbins, P.F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response. Clin. Cancer Res. (2014).
    • (2014) Clin. Cancer Res
    • Robbins, P.F.1
  • 31
    • 45549099784 scopus 로고    scopus 로고
    • Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
    • Hunder, N.N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698-2703 (2008).
    • (2008) N. Engl. J. Med , vol.358 , pp. 2698-2703
    • Hunder, N.N.1
  • 32
    • 58149483422 scopus 로고    scopus 로고
    • CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    • Yuan, J. et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA 105, 20410-20415 (2008).
    • (2008) Proc. Natl. Acad. Sci. USA , vol.105 , pp. 20410-20415
    • Yuan, J.1
  • 33
    • 0033567078 scopus 로고    scopus 로고
    • Genes encoding tumor-specific antigens are expressed in human myeloma cells
    • van Baren, N. et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94, 1156-1164 (1999).
    • (1999) Blood , vol.94 , pp. 1156-1164
    • Van Baren, N.1
  • 34
    • 22044451852 scopus 로고    scopus 로고
    • The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
    • Jungbluth, A.A. et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106, 167-174 (2005).
    • (2005) Blood , vol.106 , pp. 167-174
    • Jungbluth, A.A.1
  • 35
    • 33847377240 scopus 로고    scopus 로고
    • Cancer/testis genes in multiple myeloma: Expression patterns and prognosis value determined by microarray analysis
    • Condomines, M. et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J. Immunol. 178, 3307-3315 (2007).
    • (2007) J. Immunol , vol.178 , pp. 3307-3315
    • Condomines, M.1
  • 36
    • 33846871255 scopus 로고    scopus 로고
    • Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
    • Atanackovic, D. et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109, 1103-1112 (2007).
    • (2007) Blood , vol.109 , pp. 1103-1112
    • Atanackovic, D.1
  • 37
    • 20844432364 scopus 로고    scopus 로고
    • NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
    • van Rhee, F. et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105, 3939-3944 (2005).
    • (2005) Blood , vol.105 , pp. 3939-3944
    • Van Rhee, F.1
  • 38
    • 77957273591 scopus 로고    scopus 로고
    • Improved endpoints for cancer immunotherapy trials
    • Hoos, A. et al. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 102, 1388-1397 (2010).
    • (2010) J. Natl. Cancer Inst , vol.102 , pp. 1388-1397
    • Hoos, A.1
  • 39
    • 84904097189 scopus 로고    scopus 로고
    • Current concepts in the diagnosis and management of cytokine release syndrome
    • Lee, D.W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188-195 (2014).
    • (2014) Blood , vol.124 , pp. 188-195
    • Lee, D.W.1
  • 40
    • 84895066532 scopus 로고    scopus 로고
    • Toxicity management for patients receiving novel T-cell engaging therapies
    • Barrett, D.M., Teachey, D.T. &Grupp, S.A. Toxicity management for patients receiving novel T-cell engaging therapies. Curr. Opin. Pediatr. 26, 43-49 (2014).
    • (2014) Curr. Opin. Pediatr , vol.26 , pp. 43-49
    • Barrett, D.M.1    Teachey, D.T.2    Grupp, S.A.3
  • 41
    • 80455179612 scopus 로고    scopus 로고
    • Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    • Brentjens, R.J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828 (2011).
    • (2011) Blood , vol.118 , pp. 4817-4828
    • Brentjens, R.J.1
  • 42
    • 84906850813 scopus 로고    scopus 로고
    • T-cell immunotherapy: Looking forward
    • Corrigan-Curay, J. et al. T-cell immunotherapy: looking forward. Mol. Ther. 22, 1564-1574 (2014).
    • (2014) Mol. Ther , vol.22 , pp. 1564-1574
    • Corrigan-Curay, J.1
  • 43
    • 84962285181 scopus 로고    scopus 로고
    • Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers
    • Merchant, M. et al. Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers. J. Clin. Oncol. 33, TPS3102 (2015).
    • (2015) J. Clin. Oncol , vol.33 , pp. TPS3102
    • Merchant, M.1
  • 44
    • 84883866836 scopus 로고    scopus 로고
    • Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells
    • Cameron, B.J. et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103 (2013).
    • (2013) Sci. Transl. Med , vol.5 , pp. 197ra103
    • Cameron, B.J.1
  • 45
    • 84880730689 scopus 로고    scopus 로고
    • Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
    • Linette, G.P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863-871 (2013).
    • (2013) Blood , vol.122 , pp. 863-871
    • Linette, G.P.1
  • 46
    • 84880733312 scopus 로고    scopus 로고
    • Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology
    • Kalos, M. &June, C.H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49-60 (2013).
    • (2013) Immunity , vol.39 , pp. 49-60
    • Kalos, M.1    June, C.H.2
  • 47
    • 76249131912 scopus 로고    scopus 로고
    • Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease
    • Stein, S. et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198-204 (2010).
    • (2010) Nat. Med , vol.16 , pp. 198-204
    • Stein, S.1
  • 48
    • 0031573612 scopus 로고    scopus 로고
    • Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells
    • Levine, B.L. et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159, 5921-5930 (1997).
    • (1997) J. Immunol , vol.159 , pp. 5921-5930
    • Levine, B.L.1
  • 49
    • 84860718270 scopus 로고    scopus 로고
    • Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
    • Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra153 (2012).
    • (2012) Sci. Transl. Med , vol.4 , pp. 132ra153
    • Scholler, J.1
  • 50
    • 82555179157 scopus 로고    scopus 로고
    • Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): A phase 3 biological assignment trial
    • Krishnan, A. et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 12, 1195-1203 (2011).
    • (2011) Lancet Oncol , vol.12 , pp. 1195-1203
    • Krishnan, A.1
  • 51
    • 84891651595 scopus 로고    scopus 로고
    • Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: A meta-Analysis of phase III randomized, controlled trials
    • Sonneveld, P. et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-Analysis of phase III randomized, controlled trials. J. Clin. Oncol. 31, 3279-3287 (2013).
    • (2013) J. Clin. Oncol , vol.31 , pp. 3279-3287
    • Sonneveld, P.1
  • 52
    • 21244468338 scopus 로고    scopus 로고
    • Novel strategies in the treatment of relapsed/refractory multiple myeloma. from the Multiple Myeloma Research Foundation
    • Richardson, P. Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation. Oncology 17, 1063-1065 (2003).
    • (2003) Oncology , vol.17 , pp. 1063-1065
    • Richardson, P.1
  • 53
    • 84890096527 scopus 로고    scopus 로고
    • Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial
    • Armand, P. et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31, 4199-4206 (2013).
    • (2013) J. Clin. Oncol , vol.31 , pp. 4199-4206
    • Armand, P.1
  • 54
    • 67349107194 scopus 로고    scopus 로고
    • The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
    • Galustian, C. et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer immunology immunotherapy 58, 1033-1045 (2009).
    • (2009) Cancer Immunology Immunotherapy , vol.58 , pp. 1033-1045
    • Galustian, C.1
  • 55
    • 46749132717 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
    • Ramsay, A.G. et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118, 2427-2437 (2008).
    • (2008) J. Clin. Invest , vol.118 , pp. 2427-2437
    • Ramsay, A.G.1
  • 56
    • 84928770388 scopus 로고    scopus 로고
    • Neoantigens in cancer immunotherapy
    • Schumacher, T.N. &Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
    • (2015) Science , vol.348 , pp. 69-74
    • Schumacher, T.N.1    Schreiber, R.D.2
  • 57
    • 79955977910 scopus 로고    scopus 로고
    • Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1
    • Rajkumar, S.V. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117, 4691-4695 (2011).
    • (2011) Blood , vol.117 , pp. 4691-4695
    • Rajkumar, S.V.1
  • 58
    • 55949090299 scopus 로고    scopus 로고
    • Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma
    • Mark, T. et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br. J. Haematol. 143, 654-660 (2008).
    • (2008) Br. J. Haematol , vol.143 , pp. 654-660
    • Mark, T.1
  • 59
    • 0031710033 scopus 로고    scopus 로고
    • A third-generation lentivirus vector with a conditional packaging system
    • Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471 (1998).
    • (1998) J. Virol , vol.72 , pp. 8463-8471
    • Dull, T.1
  • 60
    • 70349833381 scopus 로고    scopus 로고
    • MIATA-minimal information about T cell assays
    • Janetzki, S. et al. "MIATA"-minimal information about T cell assays. Immunity 31, 527-528 (2009).
    • (2009) Immunity , vol.31 , pp. 527-528
    • Janetzki, S.1
  • 61
    • 80051775476 scopus 로고    scopus 로고
    • T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
    • Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
    • (2011) Sci. Transl. Med , vol.3 , pp. 95ra73
    • Kalos, M.1
  • 62
    • 77950541195 scopus 로고    scopus 로고
    • Comprehensive assessment of T cell receptor beta-chain diversity in alphabeta T cells
    • Robins, H.S. et al. Comprehensive assessment of T cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099-4107 (2009).
    • (2009) Blood , vol.114 , pp. 4099-4107
    • Robins, H.S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.